Sona Nanotech Inc

Sona Nanotech, Inc. engages in the development of multiple proprietary methods for the manufacture of various types of gold nanoparticles in medical applications. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2018-10-04. The firm is developing targeted hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The company is engaged in the development of pre-clinical nanomedical therapy for the treatment of cancer using its proprietary and biocompatible gold nanorods (GNR) leveraging on its core manufacturing technology for these biocompatible GNRs, scientific experience, accumulated study data and laboratory. The company has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.